A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

Abstract Background High-affinity tumor antigen-specific T-cell receptor (TCR) gene is required to engineer potent T cells for therapeutic treatment of cancer patients. However, discovery of suitable therapeutic TCR genes is hampered by the fact that naturally occurring tumor antigen-specific TCRs a...

Full description

Bibliographic Details
Main Authors: Junko Matsuzaki, Takemasa Tsuji, Thinle Chodon, Courtney Ryan, Richard C. Koya, Kunle Odunsi
Format: Article
Language:English
Published: BMJ Publishing Group 2019-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
NY-ESO-1
TCR gene-engineering
CD4+CD8+ double-positive T cells
HLA-A*02:01
Anti-tumor function
Adoptive cell therapy
Online Access:http://link.springer.com/article/10.1186/s40425-018-0467-y

Internet

http://link.springer.com/article/10.1186/s40425-018-0467-y

Similar Items